Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma

Koo, Dong-Hoe; Park, Inkeun; Ahn, Jin-Hee; Lee, Dae-Ho; You, Dalsan; Jeong, In-Gab; Song, Cheryn; Hong, Bumsik; Hong, Jun; Ahn, Hanjong; Lee, Jae-Lyun; Hong, Jun Hyuk
February 2016
Cancer Chemotherapy & Pharmacology;Feb2016, Vol. 77 Issue 2, p339
Academic Journal
journal article
Purpose: The purpose of the current study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who interrupted vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy.Methods: A retrospective analysis of medical records was performed on all patients with mRCC treated with VEGFR-TKIs between January 2008 and July 2014 (n = 505). Patients who achieved stable disease (SD) or a better response under TKI and later discontinued TKI treatment for any reason with the exception of disease progression were included in the analysis.Results: We identified 32 patients (sunitinib = 20, sorafenib = 7, and pazopanib = 5). The responses to VEGFR-TKIs were complete response (CR, n = 4), partial response (PR, n = 11), SD (n = 15), and controlled but nonmeasurable response (n = 2). Median time to TKI discontinuation from the initiation of VEGFR-TKI therapy was 16.6 months (95 % CI 12.8-20.3), and the main cause of VEGFR-TKI discontinuation was toxicity (n = 19, 59.4 %). At the time of analysis, 16 patients had disease progression and one patient died. With a median follow-up duration of 51.7 months (range 11.5-87.6), median progression-free survival (PFS) after TKI discontinuation was 20.2 months (95 % CI 6.4-34.0). In multivariate analysis, the duration of TKI therapy (<1 year) before TKI discontinuation was an independent significant prognostic factor of poor PFS (p = 0.045). Among 11 patients who were retreated with the same TKI, two patients (18.2 %) achieved PR and nine achieved SD (81.8 %).Conclusions: VEGFR-TKI could be interrupted at least temporarily when clinically warranted in patients with mRCC sufficiently controlled by TKIs.


Related Articles

  • Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Buchler, T.; Klapka, R.; Melichar, B.; Brabec, P.; Dušek, L.; Vyzula, R.; Abrahamova, J. // Annals of Oncology;Feb2012, Vol. 23 Issue 2, p395 

    Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the...

  • Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Poprach, A.; Pavlik, T.; Melichar, B.; Puzanov, I.; Dusek, L.; Bortlicek, Z.; Vyzula, R.; Abrahamova, J.; Buchler, T. // Annals of Oncology;Dec2012, Vol. 23 Issue 12, p3137 

    Background A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed. Patients and Methods Data on mRCC patients treated with sunitinib or sorafenib...

  • Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Grassi, Paolo; Doucet, Ludovic; Giglione, Palma; Grünwald, Viktor; Melichar, Bohuslav; Galli, Luca; De Giorgi, Ugo; Sabbatini, Roberto; Ortega, Cinzia; Santoni, Matteo; Bamias, aristotelis; Verzoni, Elena; Derosa, Lisa; Studentova, Hana; Porcu, Luca; De Braud, Filippo; Porta, Camillo; Procopio, Giuseppe // Oncology;May2017, Vol. 92 Issue 5, p269 

    Purpose: Pancreatic metastases (PM) from renal cell carcinoma (RCC) have been associated with long-term survival. The aim of this study was to evaluate the outcome of RCC patients with multiple glandular metastases (MGM) treated with targeted therapies (TTs). Methods: Sixty-four MGM patients...

  • Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Escudier, B. // Annals of Oncology;May2011, Vol. 22 Issue 5, p995 

    No abstract available.

  • Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Beuselinck, B; Wolter, P; Karadimou, A; Elaidi, R; Dumez, H; Rogiers, A; Van Cann, T; Willems, L; Body, J-J; Berkers, J; Van Poppel, H; Lerut, E; Debruyne, P; Paridaens, R; Schöffski, P // British Journal of Cancer;11/6/2012, Vol. 107 Issue 10, p1665 

    Background:The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but...

  • Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. García del Muro, Xavier; Gallardo, Enrique; García Carbonero, Iciar; Laínez, Nuria; José Méndez, María; Maroto, Pablo; Ochoa de Olza, María; Puente, Javier; Reynes, Gaspar; Rubio, José; Santander, Carmen; Suárez, Cristina; Vázquez Estévez, Sergio; Castellano, Daniel // Cancer Chemotherapy & Pharmacology;Jun2014, Vol. 73 Issue 6, p1095 

    Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques and active surveillance. But 50 % of patients may develop disease recurrence...

  • Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case. Neri, Alessandro; Lambert, Youdel; Marrelli, Daniele; Di Mare, Giulio; Mastrogiacomo, Doralba; Corso, Giovanni; Volterrani, Luca; Roviello, Franco // Surgery Today;Dec2013, Vol. 43 Issue 12, p1457 

    Gastropleural and gastropericardial fistulas are abnormal communications between the stomach and the pleural cavity or pericardium. They are rare and life-threatening complications, which require prompt surgical intervention. We report the case of a gastro-pleuro-pericardial fistula that...

  • Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma. Creel, Patricia A. // Clinical Journal of Oncology Nursing;Dec2014, Vol. 18 Issue 6, p694 

    The current standard of care for treating metastatic renal cell carcinoma is sequential therapy with vascular endothelial growth factor-targeted agents (i.e., axitinib, bevacizumab, pazopanib, sorafenib, and sunitinib) and mammalian target of rapamycin inhibitors (i.e., everolimus and...

  • Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. Riesenbeck, L.; Bierer, S.; Hoffmeister, I.; Köpke, T.; Papavassilis, P.; Hertle, L.; Thielen, B.; Herrmann, E. // World Journal of Urology;Dec2011, Vol. 29 Issue 6, p807 

    Purpose: To investigate prognostic markers in patients with metastatic renal cell carcinoma (mRCC) undergoing treatment with the tyrosine kinase inhibitors (TKIs) sorafenib (So) or sunitinib (Su). Patients and methods: Eighty-three patients with mRCC, who were treated at our institution between...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics